Company TxCell CBOE EUROPE EQUITIES
Equities
0QTN
FR0010127662
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Business Summary
TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Managers
Managers | Title | Age | Since |
---|---|---|---|
Caroline Courme
IRO | Public Communications Contact | - | 01/16/01 |
Corporate Officer/Principal | - | - | |
Matthieu Allez
PRN | Corporate Officer/Principal | - | - |
Bernard Malissen
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 61 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Duncan Mckay
CHM | Chairman | - | 12/19/12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,195,394 | 1,045,009 ( 4.505 %) | 0 | 4.505 % |
Company contact information
Sangamo Therapeutics France SAS
Les Cardoulines HT1 Allée de la Nertière
06560, Valbonne
+33 4 97 21 83 00
http://txcell.com/![address TxCell(0QTN)](https://cdn.zonebourse.com/static/address/16312285.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+23.73% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-16.52% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- TXCL Stock
- 0QTN Stock
- Company TxCell